Gilead Sciences, Inc (NASDAQ: GILD) kicked off on Friday, up 1.18% from the previous trading day, before settling in for the closing price of $116.04. Over the past 52 weeks, GILD has traded in a range of $62.07-$117.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 5.30%. While this was happening, its average annual earnings per share was recorded 72.19%. With a float of $1.24 billion, this company’s outstanding shares have now reached $1.25 billion.
Considering the fact that the conglomerate employs 17600 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 78.26%, operating margin of 28.97%, and the pretax margin is 2.4%.
Gilead Sciences, Inc (GILD) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – General Industry. The insider ownership of Gilead Sciences, Inc is 0.19%, while institutional ownership is 86.62%. The most recent insider transaction that took place on Mar 03 ’25, was worth 2,534,913. Before that another transaction happened on Feb 18 ’25, when Company’s 10% Owner bought 1,363,636 for $11.00, making the entire transaction worth $14,999,996. This insider now owns 31,424,760 shares in total.
Gilead Sciences, Inc (GILD) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.93 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 72.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 24.67% during the next five years compared to -38.13% drop over the previous five years of trading.
Gilead Sciences, Inc (NASDAQ: GILD) Trading Performance Indicators
Take a look at Gilead Sciences, Inc’s (GILD) current performance indicators. Last quarter, stock had a quick ratio of 1.45. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.09. Likewise, its price to free cash flow for the trailing twelve months is 14.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.37, a number that is poised to hit 1.77 in the next quarter and is forecasted to reach 8.43 in one year’s time.
Technical Analysis of Gilead Sciences, Inc (GILD)
Compared to the last year’s volume of 8.11 million, its volume of 12.04 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 84.40%. Additionally, its Average True Range was 2.61.
During the past 100 days, Gilead Sciences, Inc’s (GILD) raw stochastic average was set at 97.05%, which indicates a significant increase from 93.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 15.05% in the past 14 days, which was lower than the 24.67% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $99.58, while its 200-day Moving Average is $84.56. Nevertheless, the first resistance level for the watch stands at $118.96 in the near term. At $120.50, the stock is likely to face the second major resistance level. The third major resistance level sits at $122.59. If the price goes on to break the first support level at $115.33, it is likely to go to the next support level at $113.24. Now, if the price goes above the second support level, the third support stands at $111.70.
Gilead Sciences, Inc (NASDAQ: GILD) Key Stats
The company with the Market Capitalisation of 146.22 billion has total of 1,245,346K Shares Outstanding. Its annual sales at the moment are 28,754 M in contrast with the sum of 480,000 K annual income. Company’s last quarter sales were recorded 7,569 M and last quarter income was 1,783 M.
